BioXcel's Breakthrough: BXCL501 Shows Promise in Easing Opioid Withdrawal Symptoms

BioXcel Therapeutics announces positive Phase 2 results for BXCL501 in treating opioid withdrawal, showing better efficacy and tolerability than lofexidine amid the opioid crisis.